Tunicamycin

Category	Influenza Virus
CAS	11089-65-9
Description	Tunicamycin, a mixture of homologous nucleoside antibiotics, has been used to study the effect of N-linked glycosylation of human proton-coupled folate transporter (HsPCFT) in HeLa cells. Tunicamycin blocks the formation of N-glycosidic linkages by inhibiting the first step in glycoprotein synthesis. It exhibits a range of biological activities, including antimicrobial, antivirus, and antitumor effects. It is produced by certain bacteria, including Streptomyces lysosuperficus and Streptomyces chartreusis.

Quotation Now

Melting Point	234-235 °C (dec.)
Purity	≥98%
Solubility	Soluble in DMSO
Appearance	Off-white to light-yellow powder
Storage	Store at 2-8 °C, dry and sealed storage
Index Of Refraction	1.617
In Vitro	Tunicamycin (2 µg/mL; 24 hours; CD44+/CD24- and original MCF7 cells) treatment increases the spliced XBP-1, ATF6 nuclear translocation level and CHOP protein expression in CD44+/CD24- and original MCF7 cells Tunicamycin-induced ER stress suppresses CD44+/CD24- phenotype cell subpopulation and in vitro invasion and accelerates tumorosphore formation. Under effect of Tunicamycin, the results show that inhibited invasion, increased cell death, suppressed proliferation and reduced migration in the CD44+/CD24- and CD44+/CD24- rich MCF7 cell culture.
In Vivo	Tunicamycin (0.1 mg/kg or 0.5 mg/kg) treatment dramatically suppresses tumor growth in the CD133+/- MHCC97L cells xenograft model (BALB/c (nu/nu) mice).
PSA	311.82000
Target	IC50: 0.35 μM (phospho-N-acetylmuramyl-pentapeptide transferase (MraY)